Creating a new treatment for ovarian cancer using targeted antibody-drug conjugates
Development of a Novel Nectin Targeting Antibody-drug Conjugate for Ovarian Cancer Therapy
This study is testing a new treatment that combines a special antibody with a powerful drug to specifically target and attack ovarian cancer cells, aiming to give patients more effective options when they have few choices left.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Resonant Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Santa Barbara, UNITED STATES) |
| Project ID | NIH-11008628 on NIH RePORTER |
What this research studies
This research focuses on developing a novel antibody-drug conjugate (ADC) specifically designed to target ovarian cancer cells. By using a proprietary platform, the team has identified a new tumor-selective target that is overexpressed in ovarian cancer, which may also help to counteract the immunosuppressive environment of the tumor. The approach involves conjugating a cytotoxic drug to an antibody that binds to this target, allowing for precise delivery of the treatment directly to cancer cells. This method aims to improve therapeutic options for patients who currently have limited choices.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer, particularly those who have not responded well to existing therapies.
Not a fit: Patients with non-ovarian cancers or those whose ovarian cancer does not express the targeted marker may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with ovarian cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise with similar antibody-drug conjugate approaches in treating various cancers, indicating potential for success with this novel target.
Where this research is happening
Santa Barbara, UNITED STATES
- Resonant Therapeutics, INC. — Santa Barbara, United States (Active)
Researchers
- Principal investigator: Delgado, Oliver — Resonant Therapeutics, INC.
- Study coordinator: Delgado, Oliver
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.